Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Sarcoma 142Osteosarcoma 26Liposarcoma 25Leiomyosarcoma 25Histiocytoma, Malignant Fibrous 19Hemangiosarcoma 18Sarcoma, Synovial 17Neurofibrosarcoma 17Fibrosarcoma 17Rhabdomyosarcoma 16Dendritic Cell Sarcoma, Interdigitating 16Sarcoma, Ewing 13Neuroectodermal Tumors, Primitive, Peripheral 11HIV Infections 11Sarcoma, Kaposi 10Neoplasms 10Neoplasm Metastasis 10Malignant mesenchymal tumor 10Acquired Immunodeficiency Syndrome 10Lymphoma, Large B-Cell, Diffuse 9Dermatofibrosarcoma 9Ovarian Neoplasms 8Lymphoma 8Hemangiopericytoma, Malignant 8Desmoplastic Small Round Cell Tumor 8Sarcoma, Alveolar Soft Part 6Chondrosarcoma, Extraskeletal Myxoid 6Bone Neoplasms 6Chondrosarcoma 5Burkitt Lymphoma 5

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Adenocarcinoma × Doxorubicin × Sarcoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡